Alzinova collaborates with Captario to optimize clinical developmentDate: 2021-03-03
Alzinova has recently initiated a collaboration with Captario to further optimize the company's development strategies.
Alzinova is currently preparing for an upcoming Phase 1b clinical study with its therapeutic vaccine, ALZ-101 for the treatment of Alzheimer’s disease. The company is using the artificial intelligence (AI)-driven modeling and simulation capabilities of Captario SUM™ to facilitate decision making and optimize strategic development processes.
“Captario’s ability to model strategic options and compare them in real-time is very powerful. The tool has helped us to generate exciting new opportunities and ideas about how we can optimize our development program and make ALZ-101 even more attractive to potential partners” says Kristina Torfgård, CEO